Who
James B. Bucher
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Zentalis Pharmaceuticals; Chief Legal Officer, Harpoon Therapeutics; EVP and General Counsel, Climb Bio; EVP & General Counsel, Alder Biopharmaceuticals.
In numbers
- Trades disclosed
- 28
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $26K
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 3 Mar 2016
- Last trade
- 8 Jan 2026
- Last filed
- 9 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jan 2026filed 9 Jan 2026 | ZNTL Zentalis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 8 Jan 2026filed 9 Jan 2026 | ZNTL Zentalis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 1 Oct 2025filed 1 Oct 2025 | ZNTL Zentalis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 11 Mar 2024filed 11 Mar 2024 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code D | —110,000 | filing |
| 21 Dec 2023filed 26 Dec 2023 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 31 Oct 2022filed 2 Nov 2022 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —95,000 at $0.00 | filing |
| 27 Jan 2022filed 31 Jan 2022 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —95,000 at $0.00 | filing |
| 22 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —95,000 at $0.00 | filing |
| 22 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 22 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —35,000 at $0.00 | filing |
| 22 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —70,000 at $0.00 | filing |
| 22 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —70,000 at $0.00 | filing |
| 22 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —135,000 at $0.00 | filing |
| 22 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticals | SEC FORM 4 Code A | —15,619 at $0.00 | filing |
| 22 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticals | SEC FORM 4 Code U | $498K27,677 at $18.00 | filing |
| 11 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticals | SEC FORM 4 Code A | $8,317904 at $9.20 | filing |
| 31 May 2019filed 24 Oct 2019 | Alder Biopharmaceuticals | SEC FORM 4 Code A | $12K1,345 at $9.20 | filing |
| 25 Apr 2019filed 25 Apr 2019 | Alder Biopharmaceuticals | SEC FORM 4 Sold | $26K1,897 at $13.85 | filing |
| 23 Apr 2019filed 25 Apr 2019 | Alder Biopharmaceuticals | SEC FORM 4 Code A | —7,810 at $0.00 | filing |
| 6 Feb 2019filed 8 Feb 2019 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.